Three advantages to flexible-label mastitis therapy
Take the steps to avoid unnecessary risk and needlessly expensive treatment costs
By Juan Rodrigo Pedraza, DVM, Dairy Technical Services, Zoetis
Costs of re-treatments, milk loss and the spread of pathogens associated with mastitis relapse offer tremendous incentive to completely cure the disease. But too often, mastitis treatments end before the infection is completely cured, meaning bacteria may remain in the udder.
With a flexible-label mastitis treatment, you have the option to treat for up to eight days on-label to help achieve a complete bacteriological cure, which can mean more milk in the tank. Cows with complete mastitis cures gave 8.8 pounds more milk than cows not cured, according to a Cornell University study.1
Stopping treatment because clinical symptoms clear up doesn’t guarantee a complete cure. Using a mastitis treatment with a flexible-label therapy option allows you to treat once daily for up to eight consecutive days, giving you a better chance to reach a bacteriological cure.
Eliminate unnecessary risk and needlessly expensive treatment costs with these three steps:
- Tailor treatment: Examining each cow’s health history can help you and your veterinarian identify the right treatment for those difficult mastitis pathogens. As a triaging procedure, consider culture results, parity of the cow, stage of lactation, number of previous clinical mastitis cases and which quarter was affected, chronicity of the mastitis case and other persistent health issues. Once you’ve reviewed the available health information, you can consider flexible-label mastitis therapy to help tailor treatment duration to the individual case for mastitis when extra days of therapy are needed. Also, keep in mind that not every cow is a candidate for mastitis treatment.
- Achieve a complete bacteriological cure: Even though milk returning to normal signals a clinical cure, it may not equal a bacteriological cure. And the difference between the two is lost productivity and significant cost increases. Relapse that can occur after a clinical cure and before a bacteriological one also increases the risk of spreading mastitis-causing pathogens in the herd. Flexible mastitis therapy that is on-label can sometimes be necessary to achieve a bacteriological cure and help reduce the chance of relapse. SPECTRAMAST® LC (ceftiofur hydrochloride) Sterile Suspension is approved for additional treatments and provides the flexibility to continue once-daily treatment for up to eight consecutive days for more stubborn mastitis cases.
- Reduce milk loss: Without a complete bacteriological cure, mastitis can rob milk production and profit. Avoid additional losses in milk production by choosing a treatment with a label flexible enough to work longer to clear up bacteria lurking in the udder. Additionally, flexible-label therapy offers you approved milk and slaughter withholds for up to eight days of treatment per label directions.
Learn more about how to work toward achieving a complete, or bacteriological, mastitis cure with the flexible-label therapy of SPECTRAMAST LC.
IMPORTANT DIAGNOSTIC INFORMATION: SPECTRAMAST LC is intended for use in lactating dairy cattle only with the specified, labeled pathogens. To assure responsible antimicrobial drug use, it is expected that subclinical mastitis will be diagnosed using a positive culture, or other pathogen-specific test, in addition to any other, appropriate veterinary medical evaluation prior to treatment.
IMPORTANT SAFETY INFORMATION: People with known hypersensitivity to penicillin or cephalosporins should avoid exposure to SPECTRAMAST LC. Product requires a 72-hour milk discard period and a 2-day pre-slaughter withdrawal period following the last treatment. Use of this product in a manner other than indicated on the label, or failure to adhere to proper milk discard period, will result in violative residues. See full Prescribing Information.
Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 65 years of experience in animal health, Zoetis discovers, develops, manufactures and commercializes medicines, vaccines and diagnostic products, which are complemented by biodevices, genetic tests and a range of services. Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in more than 100 countries. In 2018, the company generated annual revenue of $5.8 billion with approximately 10,000 employees. For more information, visit https://www.zoetisus.com/.
For more information, contact:
1Schukken YH, Bennett GJ, Zurakowski MJ, et al. Randomized clinical trial to evaluate the efficacy of a 5-day ceftiofur hydrochloride intramammary treatment on nonsevere Gram-negative clinical mastitis. J Dairy Sci. 2011;94(12):6203-6215.
- Belgium (French)
- Belgium (Dutch)
- Costa Rica
- Czech Republic
- New Zealand
- South Africa
- South Korea
- United Kingdom
- United States